Harvard Bioscience (HBIO) Total Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Liabilities data on file, last reported at $67.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $67.9 million, up 4.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.9 million (up 4.5% YoY), and the FY2025 annual result was $66.3 million, up 4.79% from the prior year.
• Total Liabilities improved to $67.9 million in Q1 2026 per HBIO's latest filing, from $66.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $81.7 million in Q1 2022 and troughed at $61.7 million in Q2 2024.
• A 5-year average of $68.2 million and a median of $65.9 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities grew 10.16% in 2022, then retreated 13.19% in 2023.
• A 5-year view of Total Liabilities shows it stood at $73.1 million in 2022, then fell by 12.1% to $64.3 million in 2023, then slipped by 1.54% to $63.3 million in 2024, then gained by 4.79% to $66.3 million in 2025, then gained by 2.34% to $67.9 million in 2026.
• Business Quant data shows HBIO's Total Liabilities at $67.9 million in Q1 2026, $66.3 million in Q4 2025, and $63.9 million in Q3 2025.